Skip to content
FIND A HEALTH VALLEY ACTOR
Atinary

Atinary Technologies Announces Strategic Collaboration with Snapdragon Chemistry

04.10.2024
Share this article

Atinary Technologies has joined forces with Snapdragon Chemistry, a Cambrex subsidiary, to bring AI-driven automation into pharmaceutical process development

 

 

By integrating Atinary’s no-code AI platform, SDLabs™, and Snapdragon’s LabOS™ software, the partnership has developed an automated Solid-Phase Oligonucleotide Synthesizer (SPOS), designed to optimize drug synthesis processes autonomously.

This collaboration aims to improve efficiency in API development, and early results show an 18% increase in product yield and a 22% reduction in costs. Snapdragon’s lab expertise, paired with Atinary’s AI, is positioned to significantly accelerate drug R&D pipelines.

Atinary’s AI platform brings groundbreaking improvements by streamlining complex chemical and molecular discoveries, enabling faster and more efficient development than traditional methods. Snapdragon, specializing in continuous flow processes, provides the infrastructure necessary for implementing Atinary’s AI-driven optimizations. This synergy highlights the potential of combining advanced technologies to solve intricate challenges in the pharmaceutical industry.

Dr. Hermann Tribukait, CEO of Atinary, emphasized that this partnership showcases the powerful capabilities of AI in advancing scientific research and pharmaceutical production. Similarly, Dr. Eric Fang, General Manager at Snapdragon Chemistry, expressed enthusiasm for how this collaboration can further expand their technological capabilities, bringing significant value to their customers.

 

Source: Press Release